CAP-话题@MedSci

#CAP#

167篇内容 | 3510人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1898066, encodeId=91bd1898066be, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, objectType=article, longId=221380, objectId=bb87221380d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb87221380d6, replyNumber=0, likeNumber=72, createdTime=2022-11-08, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb87221380d6, moduleTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb87221380d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898056, encodeId=710d1898056aa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Medscape：2020年度医学进展盘点, objectType=article, longId=204495, objectId=af1e20449543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af1e20449543, replyNumber=0, likeNumber=86, createdTime=2021-01-27, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af1e20449543, moduleTitle=Medscape：2020年度医学进展盘点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af1e20449543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898063, encodeId=e107189806374, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床, objectType=article, longId=217668, objectId=1fca21e668fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fca21e668fc, replyNumber=0, likeNumber=67, createdTime=2022-01-17, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fca21e668fc, moduleTitle=Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fca21e668fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898055, encodeId=c411189805569, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Blood：纳米单抗Caplacizumab实际应用于TTP患者的真实临床数据, objectType=article, longId=203497, objectId=c7a020349eb3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a020349eb3, replyNumber=0, likeNumber=71, createdTime=2021-05-07, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a020349eb3, moduleTitle=Blood：纳米单抗Caplacizumab实际应用于TTP患者的真实临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7a020349eb3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898054, encodeId=4e141898054a4, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, objectType=article, longId=203477, objectId=04852034e7dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04852034e7dd, replyNumber=0, likeNumber=95, createdTime=2021-07-14, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04852034e7dd, moduleTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04852034e7dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898053, encodeId=06f518980538c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Alzheimer's & Dementia：WHICAP队列研究显示，维生素D摄入量与痴呆症风险相关, objectType=article, longId=200690, objectId=1ecc20069026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ecc20069026, replyNumber=0, likeNumber=91, createdTime=2021-07-04, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ecc20069026, moduleTitle=Alzheimer's & Dementia：WHICAP队列研究显示，维生素D摄入量与痴呆症风险相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ecc20069026)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898046, encodeId=e2f11898046e9, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=AACR 2020：Capmatinib治疗MET 14突变的NSCLC脑转移疗效, objectType=article, longId=193158, objectId=b7d619315856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7d619315856, replyNumber=0, likeNumber=72, createdTime=2020-05-11, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7d619315856, moduleTitle=AACR 2020：Capmatinib治疗MET 14突变的NSCLC脑转移疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7d619315856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898050, encodeId=eab9189805069, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=FDA批准也是**一个口服生长抑素类似物MYCAPSSA（奥曲肽）胶囊，治疗肢端肥大症, objectType=article, longId=196587, objectId=ffa019658e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffa019658e05, replyNumber=0, likeNumber=75, createdTime=2021-02-24, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffa019658e05, moduleTitle=FDA批准也是**一个口服生长抑素类似物MYCAPSSA（奥曲肽）胶囊，治疗肢端肥大症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffa019658e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898057, encodeId=8c60189805eaa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle= J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌, objectType=article, longId=204950, objectId=4b6d204950d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b6d204950d0, replyNumber=0, likeNumber=90, createdTime=2021-11-30, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b6d204950d0, moduleTitle= J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b6d204950d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898058, encodeId=b55c18980582c, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=复发性卵巢癌：Rucaparib 维持治疗优势分析, objectType=article, longId=206094, objectId=3892206094de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3892206094de, replyNumber=0, likeNumber=79, createdTime=2021-03-13, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3892206094de, moduleTitle=复发性卵巢癌：Rucaparib 维持治疗优势分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3892206094de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898052, encodeId=ce9f189805296, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用, objectType=article, longId=198102, objectId=91da198102bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91da198102bf, replyNumber=0, likeNumber=99, createdTime=2021-02-13, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91da198102bf, moduleTitle=Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91da198102bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898049, encodeId=84c1189804998, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析, objectType=article, longId=195598, objectId=203c1955983f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=203c1955983f, replyNumber=0, likeNumber=72, createdTime=2020-06-27, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=203c1955983f, moduleTitle=Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=203c1955983f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898045, encodeId=2cf2189804529, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Lancet Oncol：Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期, objectType=article, longId=187899, objectId=b0bc18e89904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0bc18e89904, replyNumber=0, likeNumber=68, createdTime=2020-08-28, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0bc18e89904, moduleTitle=Lancet Oncol：Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0bc18e89904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898048, encodeId=a10c189804890, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=XENLETA（lefamulin）治疗社区获得性肺炎（CAP）：欧盟CHMP持积极意见, objectType=article, longId=195115, objectId=8abe195115e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8abe195115e7, replyNumber=0, likeNumber=68, createdTime=2021-02-01, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8abe195115e7, moduleTitle=XENLETA（lefamulin）治疗社区获得性肺炎（CAP）：欧盟CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8abe195115e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898051, encodeId=9734189805154, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好, objectType=article, longId=197123, objectId=dc3519e123a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc3519e123a3, replyNumber=0, likeNumber=0, createdTime=2021-02-27, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc3519e123a3, moduleTitle=吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc3519e123a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898042, encodeId=9ab3189804291, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=吃瓜 | 2019Medscape年轻医生薪酬报告出炉, objectType=article, longId=179914, objectId=0fef1e99141e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fef1e99141e, replyNumber=0, likeNumber=42, createdTime=2020-08-15, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fef1e99141e, moduleTitle=吃瓜 | 2019Medscape年轻医生薪酬报告出炉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fef1e99141e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898043, encodeId=2f121898043d9, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Mater Sci Eng C Mater Biol Appl：MAO-CaP-BMP2多孔钛合金基植入物可更好的实现骨整合, objectType=article, longId=182330, objectId=51c61823300d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51c61823300d, replyNumber=0, likeNumber=67, createdTime=2020-06-22, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51c61823300d, moduleTitle=Mater Sci Eng C Mater Biol Appl：MAO-CaP-BMP2多孔钛合金基植入物可更好的实现骨整合, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51c61823300d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898047, encodeId=d53b189804eed, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=FDA：批准MET抑制剂capmatinib上市用于MET突变NSCLC的治疗, objectType=article, longId=193712, objectId=d51f193e12a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d51f193e12a7, replyNumber=0, likeNumber=86, createdTime=2020-11-26, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d51f193e12a7, moduleTitle=FDA：批准MET抑制剂capmatinib上市用于MET突变NSCLC的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d51f193e12a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898039, encodeId=16b01898039b2, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Clin Chem：在无细胞尿液中对前列腺癌无创3-MicroRNA比值模型(uCaP)的独立验证, objectType=article, longId=175827, objectId=a42d1e582770, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a42d1e582770, replyNumber=0, likeNumber=87, createdTime=2020-04-03, rootId=0, userName=smlt2008, userId=c39f145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a42d1e582770, moduleTitle=Clin Chem：在无细胞尿液中对前列腺癌无创3-MicroRNA比值模型(uCaP)的独立验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a42d1e582770)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1898041, encodeId=88881898041f7, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, objectTitle=Gastroenterology：Glecaprevir/Pibrentasvir用于索非布韦治疗失败HCV患者, objectType=article, longId=177584, objectId=0d391e7584b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d391e7584b3, replyNumber=0, likeNumber=71, createdTime=2019-08-16, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d391e7584b3, moduleTitle=Gastroenterology：Glecaprevir/Pibrentasvir用于索非布韦治疗失败HCV患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d391e7584b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAP

2020-05-29

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性

2022-11-08

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Medscape：2020年度医学进展盘点

2021-01-27

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Capricor准备将杜氏肌营养不良症 (DMD) 疗法CAP-1002推进到III期临床

2022-01-17

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Blood：纳米单抗Caplacizumab实际应用于TTP患者的真实临床数据

2021-05-07

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍

2021-07-14

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Alzheimer's & Dementia：WHICAP队列研究显示，维生素D摄入量与痴呆症风险相关

2021-07-04

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

AACR 2020：Capmatinib治疗MET 14突变的NSCLC脑转移疗效

2020-05-11

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

FDA批准也是**一个口服生长抑素类似物MYCAPSSA（奥曲肽）胶囊，治疗肢端肥大症

2021-02-24

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

J Clin Oncol：Capivasertib联合多西他赛和泼尼松龙治疗转移性去势抵抗性前列腺癌

2021-11-30

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

复发性卵巢癌：Rucaparib 维持治疗优势分析

2021-03-13

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Arthritis Rheumatol：Canakinumab在5岁及以下CAPS患者中的治疗作用

2021-02-13

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析

2020-06-27

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Lancet Oncol：Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期

2020-08-28

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

XENLETA（lefamulin）治疗社区获得性肺炎（CAP）：欧盟CHMP持积极意见

2021-02-01

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

吉利德科学：长效HIV-1衣壳抑制剂Lenacapavir（GS-6207）临床表现良好

2021-02-27

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

吃瓜 | 2019Medscape年轻医生薪酬报告出炉

2020-08-15

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Mater Sci Eng C Mater Biol Appl：MAO-CaP-BMP2多孔钛合金基植入物可更好的实现骨整合

2020-06-22

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

FDA：批准MET抑制剂capmatinib上市用于MET突变NSCLC的治疗

2020-11-26

smlt2008 (审核中...)

前往app查看评论内容

#CAP#

Clin Chem：在无细胞尿液中对前列腺癌无创3-MicroRNA比值模型(uCaP)的独立验证

2020-04-03

heli0118 (审核中...)

前往app查看评论内容

#CAP#

Gastroenterology：Glecaprevir/Pibrentasvir用于索非布韦治疗失败HCV患者

2019-08-16

科室
- - 订阅+
  - 更多科室
工具
服务